Eli Lilly vs. Teva: Which Pharmaceutical Stock Is a Better Investment for 2026?

Investors are evaluating Eli Lilly (NYSE: LLY) and Teva Pharmaceutical Industries (NYSE: TEVA) as potential picks for 2026, considering the contrasting business models and financial outlooks of these two pharmaceutical companies.

Company Profiles and Financial Performance

Eli Lilly specializes in innovative, brand-name medications primarily targeting metabolic conditions and cancer. Its key products focus on diabetes, obesity, and oncology treatment areas. Distribution of its products in the U.S. depends heavily on major wholesale distributors like McKesson Corp, Cencora Inc., and Cardinal Health, which represents a concentration risk.

In fiscal year 2025, Eli Lilly reported revenue of about $65.2 billion, marking a 44% increase from the previous year. Net income nearly doubled to $20.6 billion. The company’s debt-to-equity ratio stood at roughly 1.6 as of December 2025, with free cash flow reaching close to $9 billion.

Teva Pharmaceutical focuses on generic medications, biosimilars, and some innovative biopharmaceutical products, operating in 57 countries. Its business model is burdened by previous legal and debt challenges.

Teva’s revenue for fiscal year 2025 was about $17.3 billion, a modest 4% increase year-over-year. Net income turned positive at approximately $1.4 billion, yielding a net margin near 8.2%. Teva’s financial leverage is higher than Eli Lilly’s, with a debt-to-equity ratio around 2.2 as of December 2025, and free cash flow of about $1.2 billion.

Risks and Challenges

Both companies face significant risks impacting future performance.

  • Eli Lilly contends with competitive pressure from companies like Novo Nordisk, regulatory changes such as the Inflation Reduction Act affecting drug pricing, ongoing litigation over a drug rebate fraud case, and supply chain risks tied to reliance on suppliers in China.
  • Teva grapples with heavy debt obligations requiring substantial interest payments, intense competition and price erosion in the generics market from players like Viatris, ongoing legal issues related to past opioid lawsuits, and vulnerabilities from geopolitical and regulatory challenges affecting its global manufacturing operations.

Valuation and Market Expectations

From a valuation standpoint, Teva trades at a lower forward price-to-earnings ratio (16.4x) compared to Eli Lilly’s 33.1x, indicating Teva is less expensive relative to expected future earnings. The price-to-sales ratio for Teva is 2.3x, substantially lower than Eli Lilly’s 15.2x.

Looking ahead to 2026, Eli Lilly is anticipated to continue benefiting from its GLP-1 drugs, including Zepbound for weight loss and Mounjaro for diabetes management. These could drive revenues up to $85.2 billion and net income near $31 billion.

A new drug, Retatrutide, is expected to enhance Eli Lilly’s weight-loss portfolio. Additionally, the company is developing a small interfering RNA therapy targeting lipoprotein(a) for cardiovascular disease prevention, which analysts expect could become a blockbuster if approved.

Teva, despite having a generic GLP-1 approved, is projected to see revenue decline slightly to $16.6 billion in 2026, with net income growth to approximately $1.54 billion. The company’s portfolio includes successful generics such as Ajovy, Uzedy, and Austedo. It also plans to launch olanzapine for schizophrenia, with expectations of returning to growth by 2027.

Investment Considerations

Eli Lilly commands a premium valuation and currently appears to be the stronger growth stock owing to its innovative product pipeline and robust financial performance. Teva represents a value-oriented investment with ongoing restructuring and debt challenges.

Investors considering Eli Lilly stock should note that it was not included among the Motley Fool’s current top 10 stock recommendations, which historically have delivered above-market returns. Prospective buyers are advised to stay informed and carefully evaluate these factors before investing.

Key Takeaways

  • Eli Lilly focuses on innovative brand-name drugs with strong recent revenue and profit growth.
  • Teva specializes in generics with modest growth and higher debt levels.
  • Both companies face distinct risks from competition, regulation, litigation, and supply chain issues.
  • Valuation metrics suggest Teva is cheaper, but Eli Lilly offers stronger growth prospects.
  • Investors should consider financial health, pipeline potential, and market risks before choosing.